Clinical Trials | May 26, 2026
Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy
A one-shot gene-editing cholesterol therapy could soon be a reality
A one-shot gene-editing cholesterol therapy could soon be a reality
With standout ADC and t-cell engager response data across hard-to-treat cancers
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Access to genomic testing, not therapy cost, is the biggest challenge
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
